Eisai Co., Ltd. (ESALF)
OTCMKTS · Delayed Price · Currency is USD
32.75
+0.56 (1.74%)
Sep 2, 2025, 2:23 PM EDT
Eisai Revenue
Eisai had revenue of 202.65B JPY in the quarter ending June 30, 2025, with 7.21% growth. This brings the company's revenue in the last twelve months to 803.02B, up 9.43% year-over-year. In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B with 6.42% growth.
Revenue (ttm)
803.02B JPY
Revenue Growth
+9.43%
P/S Ratio
1.60
Revenue / Employee
73.56M JPY
Employees
10,917
Market Cap
8.91B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
Eisai News
- 4 days ago - US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug - Reuters
- 4 days ago - FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment - Investor's Business Daily
- 8 days ago - Biogen Inc (BIIB) and Eisai Launch Alzheimer's Drug LEQEMBI in Europe | BIIB stock news - GuruFocus
- 26 days ago - Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease - Seeking Alpha
- 4 weeks ago - Eisai Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Eisai Co., Ltd. (ESALF) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs - Seeking Alpha
- 4 weeks ago - Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds - Reuters